SCHEMBL25868523

SCHEMBL25868523

CC(C)Cc1ccc([N+](=O)[O-])c2nonc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTM2 P28161 9/20 0.51
GSTP1 P09211 8/20 0.51
IDO1 P14902 5/20 0.47
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
USP2 O75604 2/20 0.46
G6PD P11413 1/20 0.46
CASP6 P55212 1/20 0.46
HTT P42858 1/20 0.46
RECQL P46063 1/20 0.46
POLB P06746 1/20 0.46
TNNI3 P19429 1/20 0.46
TNNT2 P45379 1/20 0.46
TNNC1 P63316 1/20 0.46
MYC P01106 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
ALDH1A1 P00352 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10089701 0.84 GSTM2 (0.56) GSTM2GSTP1IDO1MEN1KMT2A
SCHEMBL28945749 0.82 GSTM2 (0.46) GSTM2GSTP1IDO1MEN1KMT2A
SCHEMBL28945752 0.82 GSTM2 (0.43) GSTM2GSTP1IDO1MEN1KMT2A
SCHEMBL7052057 0.80 GSTM2 (0.66) GSTM2GSTP1IDO1MEN1KMT2A
SCHEMBL8788825 0.80 GSTM2 (0.51) GSTM2GSTP1IDO1MEN1KMT2A
SCHEMBL17571734 0.78 GSTP1 (0.42) GSTM2GSTP1IDO1MEN1KMT2A
SCHEMBL25866704 0.77 GABRA1 (0.34) MEN1KMT2AUSP2HPGDHSD17B10
SCHEMBL18056297 0.76 GSTP1 (0.55) GSTM2GSTP1IDO1MEN1KMT2A
SCHEMBL2608494 0.75 GSTP1 (0.61) GSTM2GSTP1IDO1MEN1KMT2A
SCHEMBL12337785 0.73 IDO1 (0.60) GSTM2GSTP1IDO1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins UNIV YALE (US) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins ASGR1, LDLR, FCGR2A GSTM2 442/4885GSTP1 818/4885IDO1 2268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.